• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Pulmonology

Effects of s-ketamine and midazolam on respiratory variability: A randomized controlled pilot trial

byPaary BalakumarandSimon Pan
September 11, 2025
in Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Midazolam significantly reduces respiratory variability, leading to a more uniform and less adaptable breathing pattern, which may increase risk in patients with compromised respiratory function.

2. S-ketamine largely preserves respiratory variability, suggesting it may be a safer sedative option for patients who require maintenance of spontaneous breathing.

Evidence Rating Level: 1 (Excellent) 

This randomized controlled pilot trial investigated the effects of s-ketamine and midazolam on respiratory variability, an indicator of adaptability of the respiratory system, in women with fibromyalgia. Twenty-eight participants were randomized to receive intravenous infusions of s-ketamine, midazolam, or saline in a blinded, crossover design across three visits. Respiratory parameters, including mean respiratory rate, variability of respiratory rate, and variability of tidal volume, were continuously measured non-invasively using a bio-impedance method. Data from 57 experimental sessions were analyzed with linear mixed models. Midazolam significantly reduced both respiratory rate variability by 37% and tidal volume variability by 51%, without affecting mean respiratory rate. S-ketamine produced a smaller reduction in tidal volume variability (27%) but did not affect respiratory rate variability. Post hoc analysis confirmed significant differences between the two drugs across all parameters. The findings suggest that midazolam induces a more regular and less adaptable breathing pattern, whereas s-ketamine largely preserves respiratory variability. These results have clinical implications in anesthesiology and critical care, as preserved variability may be advantageous for patients requiring sedation while maintaining spontaneous breathing. Further studies in larger and more diverse patient populations are needed to determine the clinical significance of these differential effects.

Click to read this study in PLOS One

Image: PD

RELATED REPORTS

Cardiopulmonary Point-of-Care Ultrasonography for Hospitalist Management of Undifferentiated Dyspnea

Higher peak expiratory flow associated with decreased headache risk in middle-aged and older adults

GSK and Hengrui Pharma Forge $500 Million China Collaboration, Including PDE3/4 Inhibitors

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc. 

Tags: anesthesiologycritical careesketaminemidazolampulmonology
Previous Post

Cardiopulmonary Point-of-Care Ultrasonography for Hospitalist Management of Undifferentiated Dyspnea

RelatedReports

2 Minute Medicine

Cardiopulmonary Point-of-Care Ultrasonography for Hospitalist Management of Undifferentiated Dyspnea

September 10, 2025
Significant number of wrong-patient errors in radiology reports
Neurology

Higher peak expiratory flow associated with decreased headache risk in middle-aged and older adults

August 25, 2025
HOSPITAL score predicts risk of 30-day potentially avoidable readmission to hospital
Pharma

GSK and Hengrui Pharma Forge $500 Million China Collaboration, Including PDE3/4 Inhibitors

August 27, 2025
Tramadol use linked with increased risk of hypoglycemia hospitalizations
Pharma

FDA Approves First-Ever Treatment for Non-Cystic Fibrosis Bronchiectasis

August 15, 2025

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Effects of s-ketamine and midazolam on respiratory variability: A randomized controlled pilot trial
  • Cardiopulmonary Point-of-Care Ultrasonography for Hospitalist Management of Undifferentiated Dyspnea
  • Efruxifermin improves fibrosis in patients with metabolic dysfunction-associated steatohepatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.